Intranasal vaccination with the IL-18 and IL-33 adjuvanted recombinant influenza vaccine significantly enhanced antigen-specific antibody responses in systemic compartments and mucosal sites and increased mouse survival during lethal influenza challenges [76]. The gene discussed is IL18; the disease is influenza.